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Abstract: Hexadentate tris(3,4-hydroxypyridinone) ligands (THP) complex Fe3+ at very low iron con-
centrations and their high affinities for oxophilic trivalent metal ions have led to their development
for new applications as bifunctional chelators for the radiometal gallium-68 (68Ga). THP-peptide
bioconjugates rapidly and quantitatively complex 68Ga at room temperature, neutral pH, and mi-
cromolar ligand concentrations, making them amenable to kit-based radiosynthesis of 68Ga PET
radiopharmaceuticals. With the aim to produce an N-hydroxysuccinimide-(NHS)-THP reagent
for kit-based 68Ga-labeling and PET imaging, THP-derivatives were designed and synthesized to
exploit the advantages of NHS chemistry for coupling with peptides, proteins, and antibodies. The
more stable five-carbon atoms linker product was selected for a proof-of-concept conjugation and
radiolabeling study with an anti-programmed death ligand 1 (PD-L1) camelid single domain anti-
body (sdAb) under mild conditions and further evaluated for site-specific amide bond formation
with a synthesized glucagon-like peptide-1 (GLP-1) targeting peptide using solid-phase synthesis.
The obtained THP-GLP-1 conjugate was tested for its 68Ga chelating ability, demonstrating to be a
promising candidate for the detection and monitoring of GLP-1 aberrant malignancies. The obtained
sdAb-THP conjugate was radiolabeled with 68Ga under mild conditions, providing sufficient labeling
yields after 5 min, demonstrating that the novel NHS-THP bifunctional chelator can be widely used
to easily conjugate the THP moiety to different targeting molecules (e.g., antibodies, anticalins, or
peptides) under mild conditions, paving the way to the synthesis of different imaging probes with all
the advantages of THP radiochemistry.
Keywords: GLP-1; PET imaging; gallium-68; molecular imaging; molecular probe; peptides synthe-
sis; THP; hydroxypyridinone chelators; N-Hydroxysuccinimide (NHS) derivatives; single-domain
antibody; sdAb
1. Introduction
Radiometals are radioactive metal isotopes that can be exploited in medical diagnosis
and cancer therapy. To use these isotopes effectively for medical applications, the free ra-
diometal ion—present in low concentrations—must be sequestered from aqueous solution
using a chelating agent. To target the radiometal to a specific tissue, a targeting molecule is
covalently bonded to the chelating molecule used for this application, making an active
radiopharmaceutical as a diagnostic and/or radiotherapeutic agent. When the targeting
molecule, engineered with a chelator, is injected into a patient, it should deliver the radioac-
tive isotope without radiometal loss and supply an in vivo site-specific radioactive source
for imaging or therapy purpose. A quickly expanding number of radiometals with a broad
variety of characteristics (i.e., half-lives, emission types, energies, and branching ratios)
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are constantly being developed. Thanks to the wide range of generated and available ra-
dionuclides, it is currently possible to meticulously pick the specific nuclear properties that
are needed for the specific application. 68Ga, 64Cu, 86Y, 89Zr, and 44Sc are some examples
of radiometals that are currently used clinically for positron emission tomography (PET)
imaging, providing a non-invasive and sensitive method to obtain quantitative images of
many molecular processes and targets in the human body [1].
Each radiometal ion has unique coordination chemistry properties in aqueous envi-
ronments and it is thanks to these different characteristics that they can be safely used
for medical applications. The main distinction between the radioactive (hot) and the
nonradioactive (cold) metal ion chemistry is that the radiochelation is usually executed
under extremely dilute conditions, with metal ions being used in nM to pM concentrations.
As a result of these low concentrations, the chelating moiety of the radiopharmaceutical
must be coordinated efficiently by the metal in order to become clinically useful. Inter-
estingly, different radiometals used in PET imaging have multiple radioactive isotopes
that are useful for diagnostic as well as therapeutic purposes (e.g., 86/90Y, 67/68Ga, 44/47Sc,
60/61/62/64Cu), and all isotopes of a given element have identical chemistry. This means
that a same radiopharmaceutical agent can easily be labeled with different radioisotopes
with therapeutic or diagnostic properties. Radiopharmacies in hospitals have been de-
veloped around technetium-99m chemistry and protocols for labeling the tracer. When
technetium-99m (99mTc) is used as radioactive source the tracer is labeled with speed, sim-
plicity, and reproducibility from commercially available “cold kits” compatible with good
manufacturing practice (GMP) [2]. With the growth of 18F and 11C-based PET imaging
tracers, more complex and costly infrastructures have been built to support PET because a
kit model is not compatible with those tracers and due to the need for an on-site cyclotron
and more complex synthetic chemistry procedures involved in radiolabeling. Modern 68Ga
generators are compatible with GMP and have the potential to be used in the manufactur-
ing of kit-based radiotracers if a simple chelation step can be achieved [3,4], making 68Ga
tracers widely available without the costly infrastructures related with 18F and 11C produc-
tion. Despite several efforts for a kit-based 68Ga tracer production [5], an ideal one-step
procedure for gallium radiolabeling, with the same simplicity of the long-established tech-
netium labeling procedures (addition of generator eluate to the kit vial), has not yet been
widely achieved [6,7]. The current generation of 68Ga chelators does not satisfy optimal
criteria (i.e., the radiolabeling reaches completion quickly, i.e., in a matter of minutes at
room temperature, must not be affected by common trace metals, must be ready to use
without additional steps to concentrate, buffer or purify, should also resist to the in vivo
transchelation and the conjugation and radiolabeling should not produce mixtures of di-
astereomers, enantiomers, or geometric isomers with potential adverse pharmacokinetics).
Some examples of current 68Ga chelators are shown in Figure 1. Among them, DOTA [8],
which binds gallium with extraordinary stability, has very slow complexing kinetics that
requires heating and low pH conditions. Moreover, the low radiochemical yields (<95%)
require a purification step. NOTA, TRAP, and DEDPA (Figure 1) are promising chelators,
however, similarly to DOTA, their gallium complexation require acidic conditions, and the
formed complexes are particularly vulnerable to competition from contaminating trace
metals [9–12]. The DOTA series of chelators show rapid, room temperature labeling at pH
5 but require preprocessed eluate [13]. All of these disadvantages are not compatible with
a kit-based protocol and GMP.
A recent class of chelators that promises to have all the requirements for kit-based
radiolabeling are based on tris(hydroxypyridinone) (THP) [14]. THP can complex 68Ga
rapidly at room temperature and pH = 7, with high yield and chromatographically pure
compound. Its performance has previously been evaluated against a range of common
chelators, showing better properties for radiolabeling under mild conditions. THP has also
been functionalized for conjugation to peptides, proteins, and other targeting molecules
such as bisphosphonates while retaining the required mild radiolabeling and in vivo
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targeting properties [15–18]. Moreover, peptide-THP-based PET tracers have been already
tested in clinical trials with promising results [19].
Figure 1. Structures of some 68Ga chelators of current generation.
With the aim to exploit the N-hydroxysuccinimide (NHS) ester chemistry and to
produce an easy to use kit-based NHS-THP for 68Ga-labeling and PET imaging, in this
study, a “biochemically-friendly” NHS-functionalized THP-derivative was designed and
synthesized. This derivative offers the advantage of well-established NHS chemistry for
the successful and biocompatible coupling with virtually any protein sequence including
antibodies, in a single step reaction in an aqueous environment (Figure 2) [20]. NHS
ester-activated compounds react with primary amines under physiological conditions to
slightly alkaline conditions (pH 7.2 to 9) to yield stable amide bonds. The reaction only
releases NHS and does not have the limitation of the already proposed THP derivatives,
namely THP-maleimide and THP-isothiocyanate (i.e., presence of a thiol group, partial
reduction of cysteine in antibodies and/or water instability) [16,21,22]. After a biocompati-
ble reaction with the activated NHS-THP, the antibody or protein could directly be used in
PET imaging after radiolabeling. With this objective in mind, we designed two different
NHS-THP ligands and evaluated their stability and amide bond formation capabilities
under either site-selective solid-phase synthesis, or solution-phase under mild conditions.
The more stable six-carbon-atom product was selected for a proof of concept conjugation
and radiolabeling study with an anti-programmed death ligand 1 (PD-L1) camelid single
domain antibody (sdAb) MY-1502-6-51 under mild conditions and further evaluated for its
site-selective amide bond formation abilities with a synthesized glucagon-like peptide-1
(GLP-1) targeting peptide using solid-phase synthesis. The THP-GLP-1 targeting pep-
tide obtained was then evaluated for its 68Ga chelating ability, demonstrating promising
properties for the detection and monitoring of GLP-1 aberrant malignancy.
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is a 30-amino acid eptid released in the gut following th ingestion of
nu rients. It cts as a hormone by stimulating the insulin r lease from the -ce ls i
eostasis. It also inhibits glucagon production, hepatic gluconeogen sis, gastric
mobility, and suppresses appetite [23]. In line with the physiolog cal role of GLP-1, high
levels of it target receptor (GLP-1R) are expressed in the pancr atic β-cells. However, the
action of GLP-1 is strictly regulated to prevent the development of hypoglycemia b rapid
degradation an deactivation of the peptide by the action of an enzyme called dip ptidyl-
pe tidase-IV (DPP-4) [24–26]. GLP-1R has been shown to be expressed in high density
and high incidence in some types of cancers derived from endocrine, neuroendocrine, and
embryonic origins (e.g., insulinoma) [27–29].
Due to its rapid metabolism and inactivation in vivo, a bioconjugate incorporating the
original GLP-1 sequence is not suitable to target GLP-1R expression [30]. Interestingly, some
drugs that are normally used for the therapy of type 2 diabetes, despite having a different
peptide structure, retain an affinity to the GLP-1R but they are not metabolized by the
DPP-4 [31]. One example is a linear 39 amino acid peptide named Exendin-4 (Figure 3) [32].
There are several published examples (Figure 3) of a modified version of the exendin-4
adapted for the use in PET imaging. Some examples are listed in Figure 3 ([Lys40(Ahx-
DOTA)]exendin-4 [33], [Lys40(Ahx-DTPA)]exendin-4, [34] [Lys40(AhxHYNIC)]exendin-
4 [35,36], [Cys40(FBEM)]exendin-4 [37], [Cys0(FBEM)]exendin-4 [37]). In these examples,
the primary sequence of the exendin-4 was in all cases extended at the carboxylic or the
amino terminal groups with the added amino acid possessing the right characteristic for
rendering it a radiopharmaceutical agent [38].
The sequence of Exendin-4 was chosen as GLP-1 targeting peptide in this study after
the modification with the newly designed NHS-THP.
sdAbs are natural antibody fragments with a molecular weight of approximately
15 kDa, derived from a class of camelid antibodies expressed by camels and llamas. Due
to their high antigen-binding affinity, stability, and rapid blood clearance, sdAbs are
increasingly used as diagnostic and therapeutic tracers in nuclear medicine [39–41]. The
programmed cell death 1 (PD-1)/PD-L1 immune checkpoint has a key role in the immune
evasion of cancer cells in several malignancies, such as non-small cell lung cancer. Several
antibodies targeting this immune checkpoint have been granted regulatory approval in
recent years and there is an increasing need for imaging agents for the diagnosis and
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monitoring of PD-(L)1 positive malignancies. Several sdAbs targeting cancer biomarkers
such as PD-L1 or human epidermal growth factor receptor 2 are currently in clinical
development [40–42].
Figure 3. Sequence of extendin-4 and GLP-1-like radiopeptides with high binding affinity to GLP-1R.
2. Experimental Section
2.1. Synthesis
2.1.1. Materials for the Synthesis
Materials and chemicals were purchased from Acros Organics (Thermo Fisher Sci-
entific, Waltham, MA, USA) and Merck KGaA (St. Louis, MO, USA) and were reagent
grade or better. The anti-PD-L1 sdAb MY-1502-6-51 was provided by NanoMab Technology
Ltd. (Centennial Park, Elstree, Borehamwood, Hertfordshire, UK). Solvents and NMR
solvents were purchased from Fisher Scientific (Thermo Fisher Scientific, Waltham, MA,
USA) and, Merck KGaA, and VWR (Radnor, PA, USA). Silica gel for column chromatog-
raphy was purchased from Merck. All samples were dried in a vacuum oven connected
to a vacuum pump (BOC-Edwards.). Silica gel 60 F254, Merck pre-coated aluminum
sheets were employed for thin-layer chromatography (TLC) and spots were visualized
under UV light. 1H NMR and 13C NMR spectra were recorded on A Bruker Avance III
HD NanoBay 400 MHz NMR with a 5 mm 1H/13C/15N/31P QNP probe equipped with
z-gradient. Tetramethylsilane (TMS) was used in all NMR experiments as internal standard
and chemical shift (δ) values are given in ppm. General NMR Analysis Toolbox (GNAT,
v1.2, Free Software Foundation, Inc., Boston, MA, USA) was used for the analyses of NMR
experiments [43]. Low resolution mass spectra were obtained on a Thermofisher LCQ
DECA XP ion trap mass spectrometer or a Waters-Micromass ZQ-Single quadrupole mass
spectrometer. The GLP-1-THP derivative 8 and the sdAb and its conjugates were analyzed
via high-resolution-MS (direct infusion) on a Thermo Exactive Orbitrap MS operating
in ESI+ mode. Isotopic distributions were calculated using Molecular Weight Calculator
version 6.46. The resulting graph data were extracted and processed in Microsoft Excel.
Analytical RP-HPLC was carried out on a HP1050 HPLC system equipped with an au-
tosampler, a quaternary pump and a diode-array detector (DAD). The HPLC column was
a Zorbax SB C-18 2.1 mm × 10 cm (particle size 5 micron) The employed flow rate was
0.3 mL/min and the eluents were monitored at wavelengths between 210–280 nm. A linear
gradient of mobile phase B (acetonitrile (ACN) containing 0.1% trifluoroacetic acid (TFA))
over mobile phase A (0.1% TFA in water) from 0–90% B in 20 min was performed. Data
were collected and analyzed using ChemStation software. The concentration of sdAb
aliquots was determined by UV spectroscopy at a detection wavelength of 280 nm in a
Thermo Fisher NanoDrop UV spectrophotometer based on the 25,690 M−1 cm−1 calculated
extinction coefficient of MY-1502-6-51.
2.1.2. Synthesis of THP (5)
Compound 2 was prepared according to an already reported procedure [44]. The
lyophilized compound 2 (1 mmol) was dissolved in anhydrous dichloromethane (DCM)
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(1 mL) and chilled in an ice bath for 10 min. An excess of BCl3 (5 mL of a solution 1 M in
DCM) was added and the solution was stirred over a stream of nitrogen. The resulting
mixture was allowed to slowly warm to room temperature over nitrogen and then stirred
overnight. The solution was again chilled in an ice bath and methanol (50 mL) was then
added to quench the reaction. After the methanol addition, the reaction was further stirred
for 1 h. The resulting solution was evaporated under reduced pressure, dried under
high vacuum for 3 h, dissolved in a minimal amount of methanol and then precipitated
in ice-cold diethyl ether. Following centrifugation, the pellet was washed several times
with diethyl ether and finally dissolved in 50% ACN in water containing 0.1% TFA and
freeze-dried for 24 h. The freeze-dried compound 5 was used without further purification.
Yield: 99%. 1H NMR (400 MHz, DMSO (Dimethyl Sulfoxide)-d6) δ 1.81 (t, J = 8.6 Hz, 2H),
2.12 (dd, J = 11.3, 5.1 Hz, 2H), 2.66–2.42 (m, 5H), 2.98–2.83 (m, 1H), 3.90 (s, 3H), 4.57 (d,
J = 5.1 Hz, 2H), 7.33 (d, J = 4.0 Hz, 1H), 8.09 (s, 1H), 9.02 (s, 1H). 13C NMR (101 MHz,
DMSO) δ 21.11, 29.79, 30.51, 32.99, 35.24, 35.65, 39.34, 39.54, 39.75, 39.96, 40.17, 40.38, 40.59,
57.61, 113.23, 140.55, 143.10, 149.07, 159.92, 169.64, 173.89. Calculated ESI+ [M + H]+: 769.4.
Measured ESI+ [M + H]+: 769.4 (Figures S1–S3).
2.1.3. General Procedure for the Synthesis of bis-NHS-Succinnic/Glutaric Acid Ester (3,4)
To a 0 ◦C cooled solution of N-hydroxysuccinimide (27.7 mmol) in dry tetrahydrofuran
(10 mL), was added triethylamine (27.7 mmol). The appropriate acid dichloride (succinyl
chloride 3, glutaryl chloride 4) (12.6 mmol) was then added in a dropwise fashion over
10 min. The resulting white suspension was stirred for 2 h at room temperature, followed
by solvent evaporation under vacuum. The residue was taken up in DCM (100 mL) and
washed with water (3 × 50 mL). Drying over MgSO4, filtration and evaporation of the
solvent yielded a white solid (3 95%, 4 90%), which was recrystallized from isopropyl
alcohol [45].
2.1.4. General Procedure for the Synthesis of THP-Succinic/Glutaric Acid Ester (6,7)
N,N-Diisopropylethylamine (DIPEA) (6 equiv, 6 mmol) was added to compound 5
(1 mmol) in 1 mL of dimethylformamide (DMF) and then this solution was added dropwise
into a solution of bis-NHS acid ester derivative (3 or 4) (10 mmol) in DMF (5 mL) at 0 ◦C.
The reaction was monitored by MS direct infusion and HPLC-UV. All the reactions were
completed within 3 h. Reactions were dried under vacuum and chromatographed via
preparative HPLC/UV using H2O/0.1% TFA as eluent A and ACN/0.1% TFA as eluent B.
The elution program used a linear gradient of 0%–60% of eluent B in 60 min. The detection
wavelength was 281 nm and the flow rate was 15 mL/min. Only the hydrolyzed product
was then isolated for molecule 6. THP-glutaric 7; Yield: 85%; 1H NMR (400 MHz, D2O)
δ 1.72–2.82 (m, 10H), 2.04–2.12 (m, 10H), 2.30–2.43 (m, 2H), 2.65 (s, 2H), 3.73 (s, 2H), 3.77
(s, 9H), 4.53 (s, 6H), 6.88 (s, 3H). Calculated ESI+ [M + H]+: 980.4. Measured ESI+ [M + H]+:
980.4 (Figures S4 and S5).
2.1.5. Synthesis of GLP-1-Peptide-THP (8)
The precursor GLP-1-peptide-THP linear sequence was synthesized using standard Fmoc
solid-phase peptide synthesis approach. All the Fmoc-(fluorenylmethyloxycarbonyl)-amino
acid residues contained in the sequence were side-chain protected with classical acid-labile
protecting groups except from the first Lys attached to the resin that was protected with -Dde.
Rink amide resin (ProTide™, loading 0.55–0.8 mmol/g, 0.4 g) was used as solid support.
For the loading of the resin 3 equiv. (equivalents) of Fmoc-protected amino acid Lys(Dde
((1-(4,4-Dimethyl-2,6-dioxocyclohex-1-ylidene)-3-ethyl)), 3 equiv. of oxyma and 3 equiv. of
DIC (N,N′-Diisopropylcarbodiimide) were dissolved in DMF (2 mL) and the reaction mixture
was added to the resin. The reaction mixture was allowed to mix on a tube roller mixer
overnight at room temperature. The resin was then washed three times with DCM (20 mL)
and DMF (20 mL). For Fmoc-deprotection, the resin was treated two times for 15 min. with
20% piperidine/DMF (10 mL).
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A standard protocol was then used for the peptide elongation. In each step, the resin
was reacted with 4 equiv. of Fmoc-protected amino acid, 4 equiv. of oxyma, and 4 equiv. of
DIC in DMF (2 mL). The reaction mixture was allowed to mix on a tube roller mixer for
3 h at room temperature. Fmoc-deprotections were performed with 20% piperidine/DMF
(10 mL). At the end of the sequence, the last amino acid (Serine) was deprotected and
acetylated by reaction with 10 equiv. of acetic anhydride and 20 equiv. of DIPEA in a
solution of DMF (3 mL) and then added to the resin and shaken for 30 min.
After the removal of the Dde group from the lysine in presence of a solution of 2%
hydrazine in DMF (10 mL), the NHS-THP (7) was site-specifically (40Lys) coupled under
mild conditions using 5 equiv. of 7 in DMF by shaking the solution for 12 h without the
use of activation agents. After the coupling of the hexadentate tris(3,4-hydroxypyridinone)
7, the peptide was removed from the resin.
For the cleavage of the peptide from the solid phase, the resin was treated two
times for 15 min. with a solution of TFA/TIPS (triisopropylsilane)/thioanisole/water
(97/1/1/1, 10 mL). The solution was then concentrated, and the crude product was isolated
by precipitation into cold diethyl ether. The precipitate was collected by centrifugation and
dried under vacuum. The crude product was analyzed by RP-HPLC and mass spectrometry.
The final compound was chromatographed via preparative HPLC/UV using 0.1% TFA
in H2O as eluent A and 0.1% TFA in ACN as eluent B. The elution program used a linear
gradient of 0%–40% of the eluent B in 60 min. The detection wavelength was 281 nm, and
the flow rate was 15 mL/min. The isolated fractions were further analyzed by analytical
HPLC-DAD, using the same above-mentioned mobile phase of the preparative purification.
The elution program used a linear gradient of 0%–95% of eluent B in 20 min using a
C18 column at a 0.3 mL/min flow rate. Calculated ESI+ [M + 4H]4+: 1295.8860, [M +
5H]5+: 1036.9102, [M + 6H]6+: 864.2597, [M + 7H]7+: 740.9380. Measured ESI+ [M + 4H]4+:
1295.6461, M + 5H]5+: 1036.9208, [M + 6H]6+: 864.1021, [M + 7H]7+: 740.8036.
2.1.6. Synthesis of MY-1502-6-51-THP
In this preliminary set of experiments, MY-1502-6-51-THP (10) was synthesized in
20-fold and 40-fold molar excess of 7 as follows. A 50 mg/mL stock solution of 7 in
anhydrous DMSO was prepared and used immediately after preparation. To a 200 µL
aliquot of 2 mg/mL sdAb in PBS (pH 7.4), 1.03 µL (20-fold molar excess) or 2.06 µL (40-fold
molar excess) of 50 mg/mL 7 in DMSO were added, the reaction mixtures were incubated
at room temperature for 5 h. After incubation, excess 7 was removed by 6 times repeated
ultrafiltration, using centrifugal filter units with a molecular weight cut-off of 10 kDa
(Amicon, Merck Millipore). The sdAb-THP conjugate was recovered in PBS in a 1.7 mg/mL
solution after the last filtration step and stored at 2–8 ◦C until radiolabeling.
To confirm that the binding of 68Ga to the MY-1502-6-51, sdAb was THP-mediated,
a control sample was prepared in the presence of 5, a non-functionalized THP derivative
that is not expected to covalently bind to the sdAb sequence. Briefly, a 230 µl aliquot of
MY-1502-6-51 in PBS (pH 7.4), corresponding to 480 µg of protein was mixed with 11.5 µL
of a 48 mg/mL solution of 5 in DMSO, corresponding to an 18-fold molar excess of 5. The
mixture was incubated at room temperature for 5 h. Excess 5 was removed by ultrafiltration
repeated six times, using centrifugal filter units with a molecular weight cut-off of 10 kDa
(Amicon, Merck Millipore). The sdAb was recovered in PBS in a 2.2 mg/mL solution after
the last filtration step and stored at 2–8 ◦C until radiolabeling.
Calculated monoisotopic mass of [MY-1502-6-51]: 15178.3; accurate mass for [M +
10H]10+ for [MY-1502-6-51] 1518.1 (exact monoisotopic mass = 1518.8), and accurate mass
for [M + 10H]10+ for [10]: 1603.1 (exact monoisotopic mass = 1603.8).
2.2. Radiochemistry
2.2.1. Materials for 68Ga Radiolabeling of GLP-1-Peptide-THP
Gallium-68 was eluted from an Eckert & Ziegler (E&Z Radiopharma GmbH, Berlin,
Germany) 68Ge/68Ga generator producing 200–400 MBq of [68Ga]GaCl3, using hydrochlo-
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ric acid (5 mL, 0.1 M) and collected in five different fractions (1 mL). Capintec CRC-25R was
used as radiation counter. Radioactive HPLC was performed on an Agilent Technologies
1260 Infinity system equipped with degasser, UV detector (220 nm); radioactive detection
was done by a Bioscan Inc. B-FC-3200 photomultiplier tube (PMT) detector. Laura software
(LabLogic Systems Ltd., Sheffield, UK) was used to collect and analyze all radio HPLC
data. The reverse-phase method used is shown in Method 1 (Table 1).
Table 1. Method 1 for radio HPLC: A = water + 0.05% trifluoroacetic acid. B = acetonitrile + 0.05%










An Agilent Eclipse XDB-C18 column with 5 µm particle size and column dimen-
sions of 4.6 × 150 mm for the analytical reverse-phase HPLC. Radio instant thin layer
chromatography (ITLC) was developed on Agilent Technologies glass microfiber chro-
matography paper impregnated with silica gel (ITLC-SG) and analyzed using a Lablogic
Flow-count TLC scanner and a BioScan B-FC-3200 PMT detector using Laura software.
Two different ITLC methods were used: (1) the acetate method (1 M ammonium acetate
in water/methanol (1:1)); (2) citrate method (0.175 M citric acid, 0.325 M trisodium citrate
in water).
2.2.2. Sample Preparation for 68Ga Radiolabeling of GLP-1-Peptide-THP
Stock solutions of two GLP-1-peptide-THP (8) samples in water were prepared at a
concentration of 5 mg mL−1 (836 µM) using 0.8 and 0.45 mg of sample respectively. Stock
solutions were stored at −20 ◦C when not in use.
2.2.3. GLP-1-Peptide-THP Radiolabeling
5µL (4.26 nmol) of the stock solution of GLP-1-peptide-THP (8) were added to [68Ga]GaCl3
(250 µL, 5–90 MBq). Sodium bicarbonate solution in water (26 µL, 1 M) was added immedi-
ately after. The mixture was stirred, and the pH was checked to ensure it was in the range
6.5–7.5. Radiochemical yield and purity was evaluated after 5 min using ITLC by both the ac-
etate method (68Ga Rf = 0, [68Ga]Ga-THP-GLP-1 Rf = 0) and citrate method (68Ga Rf = 0.8–1,
[68Ga]Ga-THP-GLP-1 Rf = 0) and after 10 min by HPLC (Reverse phase: unbound 68Ga
retention time (Rt) = 1.9 min, [68Ga]Ga-THP-GLP-1 Rt = 13.7–13.9 min.
2.2.4. Materials for 68Ga Radiolabeling of the sdAb-THP Conjugate MY-1502-6-51-THP
Gallium-68 chloride was eluted from an Eckert & Ziegler (E&Z Radiopharma GmbH,
Berlin, Germany) 68Ge/68Ga generator in 0.1 M HCl. HPLC analyses were performed on
an Agilent Technologies 1200 HPLC system equipped with a variable wavelength detector
for UV detection at 280 nm and coupled to a Phenomenex BioSep s2000 size exclusion
chromatography column (7.8 × 300 mm, 5 µm particle size) (Phenomenex, Torrance,
California, USA) and connected to a Bioscan Inc. B-FC-3200 PMT detector (Bioscan Inc.,
Washington, DC, USA). Samples were eluted over 30 min at a flow rate of 1 mL/min in
45% ACN and 0.1% TFA in water (Method 2 for HPLC).
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2.2.5. MY-1502-6-51-THP Radiolabeling
A mixture of 30 µg (1.9 nmol) 10 in 18 µL PBS and 9 µL 1 M NaHCO3 in water
was incubated with 100 µL [68Ga]GaCl3 (ca. 15 MBq) in 0.1 M HCl for 5 min at room
temperature, the pH of the reaction mixture was around 5. Samples were analyzed by
HPLC (Method 2), 68Ga-MY-1502-6-51-THP (11) Rt = 6.7–6.8 min, unbound 68Ga eluted in
a broad peak Rt = 10.7–10.8 min. 11 was identified based on the UV signal corresponding
to 10 (Rt = 6.2–6.4 min). To confirm that the formation of 11 was THP-mediated, the same
sdAb incubated with THP(5) was radiolabeled as follows: a mixture of 44 µg MY-1502-6-51
in 22 µL PBS and 19.5 µL 1 M NaHCO3 in water were incubated with 200 µL [68Ga]GaCl3
(ca. 33 MBq) in 0.1 M HCl for 5 min; the pH of the reaction mixture was around 5. Samples
were analyzed by HPLC (Method 2).
3. Results and Discussion
3.1. Design and Synthesis of NHS–THP
With the aim to produce a kit-based NHS-THP for effortless and efficient gallium
labeling under physiological conditions, two THP-derivatives (6,7) were designed and
synthesized for exploiting the advantages of NHS chemistry for the successful and bio-
compatible coupling with antibodies and proteins [20]. With this objective in mind, we
started with the synthesis of hexadentate tris(3,4-hydroxypyridinone) (2) (Figure 4) as
already reported [44]. Once the synthesis of molecule 2 was completed, the compound
was first deprotected with BCl3 and then conjugated to two different linkers with 4- and
5- atoms. Two bis-NHS-acid esters were used as linkers: bis-NHS-succinic acid ester (3)
and bis-NHS-glutaric acid ester (4) synthesized as previously reported in literature [45]
(Figure 4), by the reaction of the respective acyl chloride (1) with NHS. Treatment of 5 with
10 equiv. of the respective bis-NHS acid ester derivative in DMF produced the activated
ester: THP-succinic (6) and glutaric (7). The reaction was monitored by ESI+ direct infusion
MS and HPLC with UV detection. The results of the monitoring were the following: for
compound 6 both direct infusion mass spectra and HPLC-DAD revealed a major presence
of the hydrolyzed acid derivative 6h, with only a small part of unhydrolyzed THP-succinic
(6). Conversely, for the other compound, 7 (THP-glutaric), the outcome was different,
and only the mass of the final molecule 7 (non-hydrolyzed NHS ester) was detected by
direct infusion MS, and just a small portion of hydrolyzed compounds 7h was detected by
HPLC/UV chromatogram for the glutaric derivative.
We hypothesized that in both cases the THP-NHS ester derivatives 6-7 were generated.
However, these compounds are very reactive under the conditions of the HPLC analysis
(dilute acidic solution), and the succinic derivative (6) decomposed instantaneously after
the addition of acidic water for the mass spectrometry analysis, probably because of its
unique planar structure with a partially non-saturated C–C bonds of its molecular skeletons
that led to this different reactivity [46]. Considering the obtained results, only the THP-
glutaric (7) was purified by preparative HPLC and analyzed for its long-term stability. The
compound was then purified via preparative HPLC/UV as described in the experimental
section. The major purified product was the THP-NHS ester derivative 7 but the acid
derivative (hydrolyzed product, compound 7h) was also collected, due to the long run
of the HPLC and to the acidic conditions. The stability data for molecule 7 are reported
in Figure 5 and Table 2. Briefly, after the preparative HPLC step, the chromatographic
purity of the collected fraction was assessed via HLPC-DAD and results showed only one
peak corresponding to the activated NHS ester derivative 7. After storing compound 7 at
−21 ◦C for 7 days, HPLC-DAD analysis was performed, and the chromatographic analysis
indicated high stability. Indeed, the major peak (89%) corresponded to the NHS ester
derivative 7 while the smaller peak corresponded to the acid derivatives 7h (11%). After
30 days at −21 ◦C, the amount of 7h remained largely unchanged (12%). Therefore 7h was
most probably formed due to initial hydrolyzation during the freeze-drying process rather
than degradation during storage. After 12 h in water solution at room temperature, as
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expected and in line with NHS chemistry, the only detected product was the hydrolyzed
ester 7h.
Figure 4. Synthetic scheme for THP-succinic (6) and THP-glutaric (7) and their hydrolysis products 6h and 6h.
Figure 5. THP-glutaric (7) preliminary stability tests. Black line, after the preparative HPLC. Red line,
after 7 days storage at −21 ◦C, dried compounds. Blue line, after 12 h incubation in water solution at
room temperature.
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Table 2. Stability tests (based on HPLC peak area ratios) of 7 (refer to Figure 5), in DMSO/DMF, PBS and over one month of
dried compound.
After the Prep HPLC After 12 h in Water Solution at RT After 7 Days at −21
◦C, Dried
Compound
NHS ester (7) acid der. (7h) NHS ester (7) acid der. (7h) NHS ester (7) acid der. (7h)
100 0 0 100 89 11
1h DMSO/DMF 1h PBS After 30 days at −21
◦C, dried
compound
NHS ester (7) acid der. (7h) NHS ester (7) acid der. (7h) NHS ester (7) acid der. (7h)
97 3 91 9 88 12
The stability of 7 over a month and in conjugation conditions: DMSO/DMF for
solid-phase synthesis and PBS for proteins/antibodies conjugation, were also verified
with excellent results and showing excellent stability over the studied period (Table 2).
Considering the promising stability results of this compound we decided to start a pilot
bio-conjugation with a peptide that binds the GLP-1 receptor, to evaluate the feasibility of
the reaction and the actual chelation properties of the bioconjugate for gallium-68.
3.2. Design and Synthesis of GLP-1-Peptide–THP
To assess the feasibility of molecule 7 to effectively form amide bonds under mild
conditions without any activation agent, a potential PET radiotracer-a peptide targeting
the GLP-1 receptor was designed and conjugated to the newly synthesized NHS-THP 7.
As already reported, the GLP-1R has been shown to be expressed in high density and
high incidence in different types of cancers derived from endocrine, neuroendocrine, and
embryonic origins (e.g., insulinoma). A PET imaging tracer can be particularly useful for the
detection of primary and small metastatic lesions and it can generally support the diagnosis,
staging and treatment monitoring of patients with GLP-1R positive malignancies.
As targeting peptide, the sequence of exendin-4 was chosen. It was already reported
that the peptide can be opportunely modified by the insertion of a terminal linker amino
acid (e.g., lysine or cysteine) without losing its activity/affinity toward the GLP-1 recep-
tor (Figure 3) and then used in PET imaging making it an active radiopharmaceutical
agent. For this study, it was decided to conjugate the same peptide (HGEGTFTSDL-
SKQMEEEAVRLFIEWLKNGGPSSGAPPPS) with a terminal lysine, then to a hexadentate
3,4-hydroxypyridinone ligand (NHS-THP 7) exploiting NHS chemistry (Figure 6). The
peptide was manually assembled using Fmoc chemistry (Figure 6 step 1). After the linear
sequence was obtained and after the removal of the Dde protecting group (Figure 6, step 2),
the 7 was coupled to the peptide (Figure 6, step 3). After the coupling of 7, the peptide was
removed from the solid support (Figure 6, step 4).
Once the synthesis of the GLP-1-peptide-THP (8) was completed, the compound
was purified via preparative HPLC/UV. The isolated fractions were further analyzed by
analytical HPLC-DAD, and the pure fractions (Figure 7) were analyzed by mass spectrom-
etry (HRMS, ESI+). The identification of the final product was confirmed by the mass
spectrometry experiments as highlighted in Figure 7, where the [M + 4H]4+, [M + 5H]5+,
[M + 6H]6+, [M + 7H]7+ of GLP-1-peptide-THP conjugate are shown.
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Figure 6. Schematic synthesis of GLP-1-peptide-THP 8.
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dif erent methods wer used in the ITLC analyses. The diff rent methods were named
“ cetate method” and “citrate method” and the results are reported in Tabl 3 and in Figures
S6–S9. A expected, the a etate method was unable to identify he chelating produc , as
under these conditions the [68Ga]Ga-GLP-1-peptide-THP (9) has a retention factor of 0 which
is the same as t at of the fr e gallium-68 ac tate (Figures S6 and S8). The citrate method,
however, coul clearly s parate free g l ium-68 from th radiolabeled peptide: In th s system,
the lab led peptide 9 has a retention factor of 0 and f e gallium-68 has a retention f ctor of
0.8–1 (Figur s S7 and S9). This result s ggests that the peptide is chelating gallium-68. Similar
results were obtained with the HPLC analyses, where a reverse phase (C18) column was
used: the results reported in Table 4 confirm the formation of 9. In the HPLC analyses, the
reverse phase system shows retention times of 1.9 and 13.7–13.9 min for unbound 68Ga and
of 9, respectively. Each analysis gave a single peak in the HPLC radiochromatograms (See
Supplementary Material, Figures S10 and S11), and under these conditions, the radiochemical
yield for all these products was >95% (determined by ITLC).
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Table 3. Results of the ITLC analysis.
Acetate Method Rf Citrate Method Rf
68Ga unbound 0 0.8–1
[68Ga]Ga-GLP-1-peptide-THP (9) 0 0
Table 4. Results of the HPLC analyses.
Reverse Phase Rt (min)
68Ga unbound 1.9
[68Ga]Ga-GLP-1-peptide-THP (9) 13.7–13.9
3.4. Synthesis of MY-1502-6-51-THP
Samples of the isolated sdAb conjugate 10, prepared with 20-fold and 40-fold mo-
lar excess of 7 were analyzed by high-resolution mass spectrometry in full-scan and in
positive electrospray ionization mode. No major difference was observed in the mass
spectra of the two conjugates: a peak corresponding to the native sdAb was observed
(see Figures S12–S14), however, in the conjugated sample, a peak corresponding to the 1:1
conjugate 10 was also detectable, demonstrating qualitatively the successful conjugation
due to amide bond formation between the sdAb and the THP-NHS ligand under mild
conditions. Conjugates with more than one THP chelator per sdAb were not identified.
Due to their similar molecular weight, it was not possible to separate sdAb from sdAb-THP
conjugates by SEC-HPLC in this preliminary study.
3.5. 68Ga Radiolabeling of MY-1502-6-51-THP
The sdAb conjugate 10 was radiolabeled with 68Ga (Figures S15–S18). Without op-
timizing radiolabeling conditions, radiolabeling yields were >90% after a 5-min incu-
bation at room temperature: 91% with the conjugate prepared in 20-fold excess of 7
(Figures S15 and S16) and 92% with the conjugate prepared in 40-fold excess of 7, no dif-
ference was observed between the two conjugates (Figure S17). The concentration of the
sdAb-THP conjugate in the reaction mixture was 15 µM, this is in line with the 7 µM con-
centration in other THP-conjugates [17,19]. The radiolabeling yield of the sdAb incubated
with the non-functionalized THP 5 was 0% confirming that the association of 68Ga with 10
was THP-mediated (Figure S18). Results are summarized in Table 5 and Figures S15–S18.
Table 5. Results of HPLC analysis of 68Ga-labeled sdAb conjugates and corresponding controls.
Radiochromatogram Rt (min) UV Rt (min)
68Ga unbound 10.7–10.8 -
[68Ga]Ga-MY-1502-6-51-THP (11) 6.7–6.8 6.2–6.4
4. Conclusions and Perspective
In this paper, we developed a versatile NHS-THP metal chelator that could be con-
jugated virtually to any targeting molecule that contains a primary amine, exploiting the
advantages of the NHS chemistry and THP for gallium radiochemistry. To demonstrate
its properties, the obtained molecule was conjugated to a GLP-1R targeting peptide and
the bioconjugate was studied for its gallium chelating capabilities showing >95% radio-
chemical yield. Even if the proposed GLP-1R targeting peptide (8) synthesis exploits a
solid-phase approach to guarantee a site-specific conjugation of the generated NHS-THP
(7) to Lys40, the same NHS-THP can enable a facile route for the preparation of other
protein conjugates containing a tris(hydroxypyridinone) chelator under mild conditions.
Particularly the developed NHS-THP (7) chelator can be used for simple, efficient labeling
of 67Ga/68Ga biomolecules under suitable conditions for peptides and proteins in aqueous
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phase and with minimal requirements of synthetic skills. This would greatly increase
67Ga/68Ga access to hospitals that lack expertise or facilities in preparation of kit-based
radiopharmaceuticals. Thus, such kit-based technologies have the potential to expand the
use of the 68Ga generator for the benefit of more hospitals and patients. The combination
of targeted imaging agents with PET allows a non-invasive diagnosis of particular cancers
with accurate delineation of the disease staging. Moreover, the uptake kinetics, the quan-
tification of the target receptor expression, and the pre-therapeutic dosimetry may allow a
more effective selection of the treatments and planning, as well as monitoring response
to the therapy and early detection of recurrent disease resulting in personalized medicine
and radiotheranostics. The main aims of individualized patient management strategies are
to optimize the treatments and to minimize risks and toxicity as well as reduce cost and
patient distress. Clinical studies with different 68Ga-based imaging agents demonstrated
the significance of individualized patient management [47–49].
It is believed that, in future clinical studies, noninvasive PET imaging with radiola-
beled tracers such as the synthesized GLP-1-peptide-THP may support the diagnosis of
particular types of cancers with overexpression of GLP-1R. Moreover, the new developed
NHS-THP represents a new way to easily conjugate the THP moiety to different targeting
molecules (e.g., antibodies, anticalins, or peptides) using either solid-phase approach such
as in this study, or a solution (non-targeted) approach, paving the way to the synthesis of
different products with all the advantages of the THP chemistry. This approach was evalu-
ated in a preliminary set of experiments with a THP conjugated sdAb and we confirmed
that the conjugate quantitatively radiolabeled with 68Ga at micromolar concentrations.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/biomedicines9040367/s1, Figure S1: ESI+ MS spectra of deprotected THP (5), Figure S2:
1H NMR of deprotected THP (5), Figure S3: 13C NMR of deprotected THP (5), Figure S4: ESI+ MS
spectra of NHS-THP-glutaric (7), Figure S5: 1H NMR of NHS-THP-glutaric (7), Figure 6S: ITLC
acetate unbound 68Ga, Figure S7: ITLC citrate unbound 68Ga, Figure S8: ITLC acetate [68Ga]Ga-GLP-
1-peptide-THP (9), Figure S9: ITLC citrate [68Ga]Ga-GLP-1-peptide-THP (9), Figure S10: Reverse
phase HPLC unbound gallium-68, Figure S11: Reverse phase HPLC [68Ga]Ga-GLP-1-peptide-THP
(9), Figure S12: ESI+ mass spectrum of MY-1502-6-51, Figure S13: ESI+ mass spectrum of MY-1502-6-
51-THP (10) (20-fold molar excess of 7), Figure S14: ESI+ mass spectrum of MY-1502-6-51-THP (10)
(40-fold molar excess of 7), Figure S15: HPLC UV chromatogram (Method 2) of MY-1502-6-51-THP
(10) (20-fold molar excess of 7), Figure S16: HPLC radiochromatogram (Method 2) of 68Ga-MY-1502-
6-51-THP (11) (20-fold molar excess of 7), Figure S17: HPLC radiochromatogram (Method 2) of
68Ga-MY-1502-6-51-THP (11) (40-fold molar excess of 7), Figure S18: HPLC radiochromatogram
(Method 2) and corresponding UV chromatograms (bottom) of 68Ga labeled MY-1502-6-51 (20-fold
molar excess of 5).
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